Davis, Terry C.; Arnold, Connie L.; Mills, Glenn; Lesser, Glenn J.; Brown, W. Mark; Schulz, Richard; Weaver, Kathryn E.; Pawloski, Pamala A. published an article in 2021, the title of the article was Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study.Related Products of 380843-75-4 And the article contains the following content:
The purpose of this pilot study was to assess Chronic Myeloid Leukemia (CML) patients adherence to, beliefs about, and barriers to oral anticancer agents (OAC) using brief self-report measures in community-based cancer clinics. Patients completed a structured interview including a health literacy assessment, a Brief Medication Questionnaire, two single-item self-report adherence questions, and the Medications Adherence Reasons Scale. Of the 86 participants, 88.4% were white; 55.8% male; mean age, 58.7 years; and 22.1% had limited health literacy. Nonadherence (missing at least one dose in the last week) was reported by 18.6% of participants and associated (p < 0.003) with less-than-excellent perceived ability to take CML medications (16.3%). Black participants reported more difficulty taking CML medications than white participants (28.6% vs. 8.3%, p = 0.053). Among all participants, 43.0% reported their CML medicine was ineffective and 24.4% that taking CML pills was somewhat to very hard. The most common reasons for missing a dose were simply missed it (24.4%) and side effects (18.6%). Most patients perceived their ability to take CML medication was good to excellent, yet nearly one in five reported missing at least one dose in the last week. Brief, no-cost self-report assessments to screen CML patients OAC adherence, barriers, and beliefs could facilitate counseling in busy community cancer clinics. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Related Products of 380843-75-4
The Article related to imatinib nilotinib dasatinib anticancer agent chronic myeloid leukemia, antineoplastic agents, chronic myelogenous leukemia, health literacy, medication adherence, self-report and other aspects.Related Products of 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics